Skip to main content
. 2007 Feb 12;64(1):67–74. doi: 10.1111/j.1365-2125.2007.02846.x

Figure 3.

Figure 3

Plasma concentration–time curves of gliclazide at steady state in CYP2C19*1 homozygotes (n = 5) (□), CYP2C19* heterozygotes (n = 9) (▵) and CYP2C19 poor metabolizers (n = 3) (Inline graphic) after multiple oral doses of 30 mg of gliclazide MR. All data indicate mean ± SE